Unity Biotechnology Inc

Unity Biotechnology — Technical Presentation (March 2023)

27 slides from Unity Biotechnology's technical presentation, Mar 27, 2023

  1. Slide 1: UBX1325 Phase 2 ENVISION nAMD Study 24 Week Data

    Arshad M. Khanani MD, MA, FASRS Director of Clinical Research at Sierra Eye Associates Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO UBX1325 Phase 2 ENVISION nAMD Study 24 Week Data Exhibit 99.2

  2. Slide 2: Special Note Regarding Forward-Looking Statements

    Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc.’s (“UNITY’s”) understanding of cellular senescence and the role it plays in diseases of aging, the pote

  3. Slide 3: Phase 2 ENVISION Study Additional Insights from Secondary Analysis

    UBX1325 Phase 2 ENVISION Study in Patients with Neovascular AMD Additional Insights from Secondary Analysis UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients wi

  4. Slide 4: Disease Pathophysiology, Rationale and Mechanism, Clinical Development Plan

    Disease Pathophysiology UBX1325 Rationale and Mechanism of Action Clinical Development Plan

  5. Slide 5: Senescent cells are Associated with Disease Pathology in AMD

    Senescent cells are Associated with Disease Pathology in AMD p16-positive senescent cells in 86y/o AMD posterior retina and choroid Drusen Astrocytes in nerve fiber layer RPE p16 p16 Bruch’s Membrane

  6. Slide 6: There is a Higher Burden of Senescent Cells in Advanced Disease

    There is a Higher Burden of Senescent Cells in Advanced Disease Percentage p16+ cells in human ocular normal (n=28), AMD (n=43) and DR/DME (n=25) samples. Each point represents a single whole globe. % of p16+ cells Disruption of Bruch’s Membrane p16+ Macular region of patient with wAMD 92-year old m

  7. Slide 7: UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells

    UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells to Restore Vascular Health and Improve Vision nAMD: Increased senescence burden Choroidal vasculature affected Neovascularization and vascular leakage Loss of vision nAMD treated with Senolytic intended results: Senescent cells rem

  8. Slide 8: UBX1325 Clinical Program Overview

    UBX1325 Clinical Program Overview Safety & Tolerability Safety & Efficacy 2020 2021 2022 2023 Phase 1 ENVISION: Phase 2 nAMD Study BEHOLD: Phase 2 DME Study Positive 24-week data previously reported SAD 24-Week Follow-up nAMD 24 Week Follow-up SAD Study - up to 10 µg 4Q ‘21 1H ‘22 2H ‘22 Long-Term E

  9. Slide 9: Clinical Context: Response of nAMD Patients to anti-VEGF Treatment

    Clinical Context: Response of nAMD Patients to anti-VEGF Treatment

  10. Slide 10: Context for AMD Data: Majority of Anti-VEGF BCVA Benefit is in First Six Months

    Context for AMD Data: Majority of Anti-VEGF BCVA Benefit is in First Six Months After Which Gains Are Limited To ~One or Fewer Letters Aflibercept AMD BLA 125387 Orig-1, 11 Nov 2011 Heier, J. S., et al and the VIEW 1 and VIEW 2 Study Groups (2012). Ophthalmology, 119(12), 2537–2548.

  11. Slide 11: UBX1325 Phase 2 ENVISION Study 24-Week Data in Patients With nAMD

    UBX1325 Phase 2 ENVISION Study 24-Week Data in Patients With nAMD 11

  12. Slide 12: ENVISION: nAMD Phase 2 Study Design

    Aflibercept Run-in Active Control Visits ENVISION: nAMD Phase 2 Study Design 24 wk. Safety & Efficacy Data Aflibercept Screening = Aflibercept injection = UBX1325 injection 48 wk. Safety & Efficacy Data Extension Visits Visit/Week -8 to -4 0 2 4 8 12 16 20 24 28 32 36 40 44 48 Sham injections of UBX

  13. Slide 13: ENVISION: nAMD Phase 2 Proof-of-Concept Study Design – Part A

    Week -16 to -8 -8 to -4 0 2 4 8 12 16 20 24 Aflibercept Run-in Follow Up Visits ENVISION: nAMD Phase 2 Proof-of-Concept Study Design – Part A Source: UBX1325-03 protocol; t_14_1_2 Safety and tolerability BCVA change from baseline CST change from baseline Non-inferiority vs aflibercept (BCVA and CST)

  14. Slide 14: ENVISION: Demographics at baseline

    ENVISION: Demographics at baseline Source: t_14_1_2 Aflibercept UBX1325 Baseline BCVA (ETDRS Letters) n 25 25 Mean 62.4 58.0 SD 9.46 13.47 Median 64.0 60.0 Min, Max 36.0, 77.0 25.0, 79.0 Baseline CST (µm) n 25 25 Mean 367.5 370.8 SD 151.75 108.85 Median 284.0 374.0 Min, Max 198.0, 683.0 206.0, 665.0

  15. Slide 15: Summary of Treatment Emergent Adverse Events

    Summary of Treatment Emergent Adverse Events Source: t_14_3_1_4 * Unrelated to treatment Aflibercept 2mg Total 25 n (%) UBX1325 10µg Total 25 n (%) Subjects with at least one TEAE 19 (76.0) 20 (80.0) Grade ≥3 TEAE 1 (4.0) 2 (8.0) Serious TEAE 0 2 (8.0) Ocular TEAE for Study Eye 14 (56.0) 15 (60.0) T

  16. Slide 16: Change from baseline in BCVA excluding post-rescue data

    Change from baseline in BCVA excluding post-rescue data UBX1325 Patients Maintained BCVA Through 24 Weeks; non-inferiority not met Source: f_14_2_1_1_a; t_14_2_1_1 3.1 ETDRS letters -0.8 ETDRS letters Average CFBL Weeks 16 – 24 ETDRS letters (85% CI) Aflibercept 2.9 (0.7 – 5.1) UBX1325 -1.1 (-3.6 –

  17. Slide 17: Change from baseline in BCVA including post-rescue data

    Change from baseline in BCVA including post-rescue data UBX1325 patients maintained BCVA through 24 Weeks Source: f_14_2_1_2_a; t_14_2_1_2 Average CFBL Weeks 16 – 24 ETDRS letters (85% CI) Aflibercept 2.5 (0.5 – 4.5) UBX1325 -1.4 (-3.4 – 0.7) 2.3 ETDRS letters -1.1 ETDRS letters UBX1325 dosed at 0 a

  18. Slide 18: Change from baseline in CST excluding post-rescue data

    Change from baseline in CST excluding post-rescue data Delayed impact on CST is consistent with potential time-course for senolytic mechanism to exert effect Source: f_14_2_1_3 Average CFBL Weeks 16 – 24 µm (85% CI) Aflibercept 11.3 (-4.9 – 27.4) UBX1325 84.0 (65.8 – 102.3) 87.3 µm 30.5 µm UBX1325 d

  19. Slide 19: Change from baseline in CST including post-rescue data

    Change from baseline in CST including post-rescue data Anti-VEGF rescue appears to improve CST in UBX1325-treated patients Source: f_14_2_1_4 Average CFBL Weeks 16 – 24 µm (85% CI) Aflibercept 10.5 (-7.0 – 28.1) UBX1325 49.4 (31.4 – 67.3) 60.9 µm 29.3 µm UBX1325 dosed at 0 and 4 weeks Aflibercept do

  20. Slide 20: Impact of AMD diagnosis duration on BCVA response

    Impact of AMD diagnosis duration on BCVA response excluding post-rescue data Patients with AMD diagnosis over two years may show stronger treatment effect with UBX1325* Source: f_14_2_3_17 UBX1325 dosed at 0 and 4 weeks Aflibercept dosed at 0, 8, and 16 weeks * Post hoc analysis expanding on a prior

  21. Slide 21: BCVA change in patients with wAMD diagnosis >2 years

    BCVA change in patients with wAMD diagnosis >2 years excluding post-rescue data is similar between UBX1325 and aflibercept-treated patients* Source: f_14_2_3_17; t_14_2_3_17 Average CFBL Weeks 16 – 24 ETDRS letters (85% CI) Aflibercept 1.9 (-0.2 – 4.0) UBX1325 1.6 (-1.3 – 4.4) UBX1325 dosed at 0 and

  22. Slide 22: ENVISION: Durability of effect of UBX1325

    ENVISION: Durability of effect of UBX1325 Majority of patients went 24 weeks without requiring anti-VEGF treatments Source: f_14_2_4_1; f_14_2_4_4_all_aflib_swimmer Maximal aVEGF-Free Interval # of aVEGF Treatments over 24 Weeks Treatment Criteria (either): Loss of 10 letters from any highest value

  23. Slide 23: Patients in ENVISION were high-need patients with active disease

    Patients in ENVISION were high-need patients with active disease requiring anti-VEGF treatment approximately every 6 weeks Source: f_prior_avegf; f_correlation_tranch1_tables Avg prior aVEGF use from -190d: 4.0 CST 370.8 µm Avg prior aVEGF use from -190d: 4.5 CST 367.5

  24. Slide 24: In UBX1325-treated patients 52% went without requiring anti-VEGF

    In UBX1325-treated patients 52% went without requiring anti-VEGF Source: f_prior_avegf; f_correlation_tranch1_tables

  25. Slide 25: Summary of UBX1325 ENVISION Phase 2 Study in nAMD

    Summary of UBX1325 ENVISION Phase 2 Study in nAMD Was generally well tolerated with no intraocular inflammation Maintained visual acuity through 24 weeks in patients with active disease; there was a 3.5 letter gain in aflibercept arm at 2 weeks and non-inferiority to aflibercept was not met May have

  26. Slide 26: Summary and Development Plans for UBX1325

    Summary and Development Plans for UBX1325 Additional Insights from Secondary Analysis UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active dise

  27. Slide 27: Q&A

    27 UNIT Y BIOTECHNOLOGY Q&A

Unity Biotechnology — Technical Presentation (March 2023) on 6ix